DK1642897T3 - Alfa-krystalform af strontiumranelat, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse - Google Patents

Alfa-krystalform af strontiumranelat, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse

Info

Publication number: DK1642897T3
Authority: DK; Denmark
Prior art keywords: preparation; pharmaceutical compositions; compositions containing; crystal form; strontium ranelate
Prior art date: 2004-09-30

Application number

DK05291297T

Other languages

Danish (da)

English (en)

Inventor

Stephane Horvath

Isabelle Demuynck

Gerard Damien

Original Assignee

Servier Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-30

Filing date

2005-06-17

Publication date

2009-01-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34942420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1642897(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-06-17 Application filed by Servier Lab filed Critical Servier Lab

2009-01-26 Application granted granted Critical

2009-01-26 Publication of DK1642897T3 publication Critical patent/DK1642897T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Physical Education & Sports Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Fodder In General (AREA)
Steroid Compounds (AREA)

DK05291297T 2004-09-30 2005-06-17 Alfa-krystalform af strontiumranelat, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse DK1642897T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0410335A FR2875807B1 (fr)	2004-09-30	2004-09-30	Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number	Publication Date
DK1642897T3 true DK1642897T3 (da)	2009-01-26

Family

ID=34942420

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK05291297T DK1642897T3 (da)	2004-09-30	2005-06-17	Alfa-krystalform af strontiumranelat, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse

Country Status (42)

Country	Link
US (2)	US7459568B2 (de)
EP (2)	EP1642897B9 (de)
JP (2)	JP2006104184A (de)
KR (1)	KR100816590B1 (de)
CN (1)	CN100391956C (de)
AP (1)	AP1930A (de)
AR (1)	AR049395A1 (de)
AT (1)	ATE411308T1 (de)
AU (1)	AU2005202718B2 (de)
BR (1)	BRPI0502228A (de)
CA (1)	CA2508824C (de)
CO (1)	CO5710195A1 (de)
CR (1)	CR7876A (de)
CY (1)	CY1108797T1 (de)
DE (1)	DE602005010359D1 (de)
DK (1)	DK1642897T3 (de)
EA (1)	EA008474B1 (de)
EC (1)	ECSP055859A (de)
ES (1)	ES2314593T3 (de)
FR (1)	FR2875807B1 (de)
GE (1)	GEP20074106B (de)
GT (1)	GT200500130A (de)
HK (1)	HK1086260A1 (de)
HR (1)	HRP20080652T3 (de)
IL (1)	IL169237A (de)
MA (1)	MA27815A1 (de)
MX (1)	MXPA05006407A (de)
NO (1)	NO333948B1 (de)
NZ (1)	NZ540802A (de)
OA (1)	OA13013A (de)
PA (1)	PA8638201A1 (de)
PE (1)	PE20060364A1 (de)
PL (1)	PL1642897T3 (de)
PT (1)	PT1642897E (de)
RS (1)	RS51110B (de)
SA (1)	SA05260168B1 (de)
SG (1)	SG121035A1 (de)
SI (1)	SI1642897T1 (de)
TW (1)	TWI367881B (de)
UA (1)	UA80008C2 (de)
WO (1)	WO2006035122A1 (de)
ZA (1)	ZA200504937B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2875807B1 (fr) *	2004-09-30	2006-11-17	Servier Lab	Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
US20070292529A1 (en) *	2006-06-19	2007-12-20	Tabbiner Philip S	Strontium compositions and methods of treating osteoporotic conditions
US20070292535A1 (en) *	2006-06-19	2007-12-20	Tabbiner Philip S	Strontium compositions and methods of treating arthritic and or osteoporitic conditions
CN101206208B (zh) *	2006-12-19	2011-08-10	北京德众万全药物技术开发有限公司	一种用hplc法分析雷尼酸锶原料及其制剂的方法
CN102227419A (zh) *	2008-09-29	2011-10-26	拉蒂奥法姆有限责任公司	无水和水合形式的雷奈酸锶
IT1398542B1 (it)	2010-03-05	2013-03-01	Chemelectiva S R L	Processo per la preparazione di un polimorfo
CN102241663B (zh) *	2010-05-10	2013-02-13	山东方明药业集团股份有限公司	一种雷奈酸锶八水合物的制备方法
WO2012143932A1 (en) *	2011-04-21	2012-10-26	Shilpa Medicare Limited	Crystalline strontium ranelate form-s
CZ2011320A3 (cs)	2011-05-30	2012-12-12	Zentiva, K.S.	Stabilní krystalická forma X stroncium ranelátu
EP2530068A1 (de)	2011-05-31	2012-12-05	Lacer, S.A.	Neue Strontiumsalze, deren Synthese und Verwendung bei der Behandlung von Osteoporose
US9301945B2 (en)	2011-07-21	2016-04-05	Emory University	Methods for treating inflammatory conditions and states, and cancers by antagonizing NF-κB activation
CN102503931A (zh) *	2011-09-20	2012-06-20	浙江华海药业股份有限公司	一种雷尼酸锶晶形h的制备方法
WO2013113319A1 (en) *	2012-01-31	2013-08-08	Pharmathen S.A.	Process for the preparation of strontium ranelate, intermediate or hydrates thereof
EP2641905A1 (de)	2012-03-23	2013-09-25	Urquima S.A.	Feste Formen von Strontiumranelat und Verfahren zu ihrer Herstellung
US8569514B1 (en)	2012-05-17	2013-10-29	Divi's Laboratories, Ltd.	Process for the preparation of strontium ranelate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2651497B1 (fr) *	1989-09-01	1991-10-25	Adir	Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.
ZA956029B (en)	1994-07-22	1997-01-20	Lilly Co Eli	Combination treatment for inhibiting bone loss
FR2749759B1 (fr) *	1996-06-17	1999-11-26	Adir	Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
DE19642451A1 (de)	1996-10-15	1998-04-16	Merck Patent Gmbh	Aminothiophencarbonsäureamide
IL161164A0 (en) *	2001-10-03	2004-08-31	Teva Pharma	Preparation of levofloxacin and forms thereof
EP2272501B1 (de) *	2002-01-09	2013-03-20	Emisphere Technologies, Inc.	Polymorphe von Natrium 4-((4-chlor-2-hydroxybenzoyl) amino) butanoat
JP2006508909A (ja) *	2002-08-06	2006-03-16	テバファーマシューティカルインダストリーズリミティド	ガチフロキサシンの新規な結晶形
FR2844795B1 (fr) *	2002-09-24	2004-10-22	Servier Lab	Nouveau procede de synthese industriel du ranelate de strontium et de ses hydrates
FR2844797B1 (fr) *	2002-09-24	2004-10-22	Servier Lab	Nouveau procede de synthese industriel des tetraesters de l'acide 5-[bis (carboxymethyl)]-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2844796A1 (fr) *	2002-09-24	2004-03-26	Servier Lab	Nouveau procede de synthese industrielle du diester methylique de l'acide 5-amino-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2875807B1 (fr) *	2004-09-30	2006-11-17	Servier Lab	Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

2004
- 2004-09-30 FR FR0410335A patent/FR2875807B1/fr not_active Expired - Fee Related
2005
- 2005-05-24 PE PE2005000574A patent/PE20060364A1/es not_active Application Discontinuation
- 2005-05-26 MA MA28300A patent/MA27815A1/fr unknown
- 2005-05-27 GT GT200500130A patent/GT200500130A/es unknown
- 2005-05-30 CA CA002508824A patent/CA2508824C/fr not_active Expired - Fee Related
- 2005-05-31 AP AP2005003323A patent/AP1930A/xx active
- 2005-05-31 US US11/140,822 patent/US7459568B2/en not_active Expired - Fee Related
- 2005-06-02 OA OA1200500169A patent/OA13013A/fr unknown
- 2005-06-14 AR ARP050102423A patent/AR049395A1/es not_active Application Discontinuation
- 2005-06-15 CR CR7876A patent/CR7876A/es not_active Application Discontinuation
- 2005-06-15 MX MXPA05006407A patent/MXPA05006407A/es active IP Right Grant
- 2005-06-15 SA SA05260168A patent/SA05260168B1/ar unknown
- 2005-06-16 IL IL169237A patent/IL169237A/en not_active IP Right Cessation
- 2005-06-16 EC EC2005005859A patent/ECSP055859A/es unknown
- 2005-06-16 CN CNB2005100753929A patent/CN100391956C/zh not_active Expired - Fee Related
- 2005-06-16 CO CO05058754A patent/CO5710195A1/es not_active Application Discontinuation
- 2005-06-17 TW TW094120331A patent/TWI367881B/zh not_active IP Right Cessation
- 2005-06-17 UA UAA200505970A patent/UA80008C2/uk unknown
- 2005-06-17 SI SI200530490T patent/SI1642897T1/sl unknown
- 2005-06-17 RS RSP-2008/0506A patent/RS51110B/sr unknown
- 2005-06-17 GE GEAP20058848A patent/GEP20074106B/en unknown
- 2005-06-17 PT PT05291297T patent/PT1642897E/pt unknown
- 2005-06-17 SG SG200503938A patent/SG121035A1/en unknown
- 2005-06-17 EP EP05291297A patent/EP1642897B9/de not_active Revoked
- 2005-06-17 ZA ZA200504937A patent/ZA200504937B/en unknown
- 2005-06-17 NZ NZ540802A patent/NZ540802A/en not_active IP Right Cessation
- 2005-06-17 EP EP08007270A patent/EP1944302A1/de not_active Withdrawn
- 2005-06-17 WO PCT/FR2005/001515 patent/WO2006035122A1/fr active Application Filing
- 2005-06-17 DK DK05291297T patent/DK1642897T3/da active
- 2005-06-17 PL PL05291297T patent/PL1642897T3/pl unknown
- 2005-06-17 AT AT05291297T patent/ATE411308T1/de active
- 2005-06-17 AU AU2005202718A patent/AU2005202718B2/en not_active Ceased
- 2005-06-17 BR BRPI0502228-2A patent/BRPI0502228A/pt not_active IP Right Cessation
- 2005-06-17 EA EA200500842A patent/EA008474B1/ru not_active IP Right Cessation
- 2005-06-17 DE DE602005010359T patent/DE602005010359D1/de active Active
- 2005-06-17 JP JP2005177199A patent/JP2006104184A/ja active Pending
- 2005-06-17 ES ES05291297T patent/ES2314593T3/es active Active
- 2005-06-17 NO NO20052998A patent/NO333948B1/no not_active IP Right Cessation
- 2005-07-01 PA PA20058638201A patent/PA8638201A1/es unknown
- 2005-07-08 KR KR1020050061542A patent/KR100816590B1/ko not_active IP Right Cessation
2006
- 2006-05-29 HK HK06106187A patent/HK1086260A1/xx not_active IP Right Cessation
2008
- 2008-08-12 US US12/228,381 patent/US7745482B2/en not_active Expired - Fee Related
- 2008-11-19 CY CY20081101327T patent/CY1108797T1/el unknown
- 2008-12-16 HR HR20080652T patent/HRP20080652T3/xx unknown
2010
- 2010-01-07 JP JP2010001847A patent/JP2010132669A/ja active Pending

Also Published As

Publication number	Publication date
US20060069271A1 (en)	2006-03-30
US7459568B2 (en)	2008-12-02
CO5710195A1 (es)	2006-12-29
TW200610758A (en)	2006-04-01
ECSP055859A (es)	2006-09-18
BRPI0502228A (pt)	2006-05-09
ES2314593T3 (es)	2009-03-16
MA27815A1 (fr)	2006-04-03
US20080312314A1 (en)	2008-12-18
US7745482B2 (en)	2010-06-29
ATE411308T1 (de)	2008-10-15
EP1642897B1 (de)	2008-10-15
SI1642897T1 (sl)	2009-02-28
PL1642897T3 (pl)	2009-04-30
DE602005010359D1 (de)	2008-11-27
NZ540802A (en)	2006-11-30
TWI367881B (en)	2012-07-11
FR2875807A1 (fr)	2006-03-31
NO20052998D0 (no)	2005-06-17
PA8638201A1 (es)	2006-05-16
CA2508824C (fr)	2009-03-24
IL169237A (en)	2010-12-30
AR049395A1 (es)	2006-07-26
EA200500842A1 (ru)	2006-04-28
EP1944302A1 (de)	2008-07-16
AU2005202718A1 (en)	2006-04-13
CY1108797T1 (el)	2014-04-09
SA05260168B1 (ar)	2009-02-25
CN100391956C (zh)	2008-06-04
EA008474B1 (ru)	2007-06-29
CA2508824A1 (fr)	2006-03-30
OA13013A (fr)	2006-11-10
GEP20074106B (en)	2007-05-10
WO2006035122A1 (fr)	2006-04-06
CR7876A (es)	2007-12-10
NO333948B1 (no)	2013-10-28
FR2875807B1 (fr)	2006-11-17
HRP20080652T3 (en)	2009-01-31
EP1642897A1 (de)	2006-04-05
HK1086260A1 (en)	2006-09-15
EP1642897B9 (de)	2009-08-12
CN1754878A (zh)	2006-04-05
AP1930A (en)	2008-12-15
RS51110B (sr)	2010-10-31
UA80008C2 (uk)	2007-08-10
KR20060049966A (ko)	2006-05-19
AU2005202718B2 (en)	2010-09-16
SG121035A1 (en)	2006-04-26
PE20060364A1 (es)	2006-06-17
GT200500130A (es)	2005-12-20
MXPA05006407A (es)	2006-04-05
JP2006104184A (ja)	2006-04-20
PT1642897E (pt)	2008-11-27
ZA200504937B (en)	2006-04-26
AP2005003323A0 (en)	2005-06-30
NO20052998L (no)	2006-03-31
KR100816590B1 (ko)	2008-03-24
JP2010132669A (ja)	2010-06-17

Publication	Publication Date	Title
DK1752443T3 (da)	2012-10-22	Ny krystallinsk form V af agomelatin, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende dette
DK1896364T3 (da)	2011-02-28	Pulverformet kalksammensætning, fremgangsmåde til fremstilling deraf og anvendelse deraf
DK1667986T3 (da)	2013-05-06	Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
DK1564202T3 (da)	2008-12-15	Ny fremgangsmåde til fremsitlling af og en ny krystalform af agomelation samt farmaceutiske sammensætninger indeholdende denne
DK1707562T3 (da)	2008-10-13	Krystallinsk v-form af ivabradin-hydrochlorid, fremgangsmåde til fremstilling heraf og famaceutiske sammensætninger, som indeholder denne
DK1695710T3 (da)	2008-09-22	Krystallinsk betad-form af ivabradinhydrochlorid, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende denne
DK1642897T3 (da)	2009-01-26	Alfa-krystalform af strontiumranelat, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
DK1695709T3 (da)	2008-09-29	Krystalinsk gammad-form af ivabradin-hydrochlorid, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende denne
DK1913001T3 (da)	2013-10-21	(r)-n-methylnaltrexon, fremgangsmåder til syntese og farmaceutisk anvendelse heraf
IS7543A (is)	2004-11-22	Bensóþíadíasepínafleiður, aðferðir til framleiðslu þeirra og lyfjablöndur sem innihalda þær
DK3305776T3 (da)	2019-12-09	Pyrrol-forbindelser som inhibitorer af erk-protein-kinaser og farmaceutiske sammensætninger, der indeholder disse forbindelser
DK1695965T3 (da)	2008-12-15	Krystallinsk betaform af ivabradin-hydrochlorid, fremgangsmåde til fremstilling heraf og famceutiske sammensætninger indeholdende denne
DK2056964T3 (da)	2019-05-06	Hidtil ukendt molekylsigtesammensætning, fremgangsmåde til fremstilling deraf og fremgangsmåde til anvendelse deraf
DK1909764T3 (da)	2014-12-15	Farmaceutisk sammensætninger omfattende levetiracetam og fremgangsmåde til deres fremstilling
IS8024A (is)	2005-09-14	Adamantanafleiður, aðferðir til að framleiða þær og lyfjablanda sem inniheldur þær
DK2036892T3 (da)	2010-06-07	1,2,4,5-tetrahydro-3H-benzazepinforbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
DK1720544T3 (da)	2008-07-21	Nye azabicykliske derivater, fremstillingsmetode hertil og farmaceutiske sammensætninger indeholdende disse
DK1862158T5 (da)	2013-03-04	Farmaceutisk sammensætning til behandling af depression og fremgangsmåde til fremstilling deraf
DK2038294T3 (da)	2011-03-28	18-methyl-19-nor-androst-4-en-17,17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-oner) og farmaceutiske præparater, der indeholder disse
DK1601363T3 (da)	2012-09-03	Anvendelse som lægemiddel af derivater af cholest-4-en-3-on, farmaceutiske sammensætninger indeholdende disse og nye derivater
DK1813678T3 (da)	2014-08-11	Fremgangsmåde til fremstilling af glycogen
DK2042497T3 (da)	2010-06-07	Fremgangsmåde til syntese af strontiumranelat og hydrater heraf
DK2172207T3 (da)	2013-04-08	Farmaceutisk sammensætning til behandling af diabetes og fremgangsmåde til fremstilling heraf
DK1560826T3 (da)	2006-08-14	Pyridopyrimidinonderivater, fremgangsmåde til fremstiling heraf og farmaceutiske sammensætninger indeholdende disse
DK1707564T3 (da)	2008-01-21	Indanyl-piperazinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse